Market Overview

UPDATE: Morgan Stanley Reiterates On Envision Healthcare As New Contract Wins Drive Growth

Share:
Related EVHC
ICON Is Now A Strong Buy: Should It Be In Your Portfolio?
UPDATE: Bank Of America Reiterates On Envision Healthcare After Phoenix Deal Closes

In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on Envision Healthcare Holdings (NYSE: EVHC), but removed the $33.00 price target.

In the report, Morgan Stanley noted, “EVHC reported 1Q14 adj. EBITDA of $110M vs. consensus of $111.5M and MS' est. of $114.2M. EmCare and AMR reported adj. EBITDA of $71.4M and $38.6M, respectively. Both segments were propelled by new contract wins/starts. However, EmCare new contract revenue was offset by a $6.7M increase in start-up compensation costs due to buyout provisions, sign on bonuses, and temporary staffing costs. However, going forward, the company has modified its contracts so clients will share the costs for accelerated starts in under 60 days.”

Envision Healthcare closed on Wednesday at $34.41.

Latest Ratings for EVHC

DateFirmActionFromTo
Feb 2015BarclaysMaintainsOverweight
Jan 2015CitigroupDowngradesBuyNeutral
Nov 2014CitigroupMaintainsBuy

View More Analyst Ratings for EVHC
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (EVHC)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content